Zeus Hygia Lifesciences has launched Metaberine®, a next-generation berberine formulation, in the Europe and US markets. 

Developed using the company’s proprietary BioSOLVE Technology, the formulation is designed to overcome the long-standing limitations of conventional berberine by significantly improving its absorption and effectiveness in the body.

Metaberine has been developed to enhance the utilisation of berberine for metabolic health support, including blood sugar regulation, insulin sensitivity, and healthy weight management. 

“Metaberine focuses on improving delivery rather than increasing dosage,” said Arunkanth Krishnakumar, Co-founder and CEO, Zeus Hygia Lifesciences. “By enhancing absorption, it supports key metabolic pathways more efficiently, including those linked to blood sugar regulation, energy utilisation, and weight management.”

A key mechanism associated with Metaberine® is its role in supporting the GLP-1 pathway, which is linked to insulin response, appetite regulation, and glucose balance. By supporting this pathway, the formulation aims to help the body manage blood sugar levels more effectively while contributing to improved satiety and reduced cravings.

The company is positioning Metaberine® for B2B collaborations across pharmaceutical, nutraceutical, and functional food sectors, supporting the development of next-generation products focused on metabolic health, blood sugar support, and healthy weight management.